JP2012080900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012080900A5 JP2012080900A5 JP2012000185A JP2012000185A JP2012080900A5 JP 2012080900 A5 JP2012080900 A5 JP 2012080900A5 JP 2012000185 A JP2012000185 A JP 2012000185A JP 2012000185 A JP2012000185 A JP 2012000185A JP 2012080900 A5 JP2012080900 A5 JP 2012080900A5
- Authority
- JP
- Japan
- Prior art keywords
- age
- macular degeneration
- related macular
- individual
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010064930 age-related macular degeneration Diseases 0.000 claims 27
- 238000000034 method Methods 0.000 claims 23
- 208000002780 macular degeneration Diseases 0.000 claims 20
- 101150030967 CFH gene Proteins 0.000 claims 12
- 238000012216 screening Methods 0.000 claims 11
- 108010053085 Complement Factor H Proteins 0.000 claims 9
- 108700028369 Alleles Proteins 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 7
- 102100035432 Complement factor H Human genes 0.000 claims 5
- 102000054766 genetic haplotypes Human genes 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 2
- 238000003205 genotyping method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102220005747 rs1061170 Human genes 0.000 claims 2
- 102210039666 rs1329428 Human genes 0.000 claims 2
- 102220130080 rs3753396 Human genes 0.000 claims 2
- 102210007338 rs380390 Human genes 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 239000012633 leachable Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62936304P | 2004-11-18 | 2004-11-18 | |
| US60/629,363 | 2004-11-18 | ||
| US64947905P | 2005-02-02 | 2005-02-02 | |
| US60/649,479 | 2005-02-02 | ||
| US67234605P | 2005-04-18 | 2005-04-18 | |
| US60/672,346 | 2005-04-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543226A Division JP2008520242A (ja) | 2004-11-18 | 2005-11-18 | 視覚障害を処置するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012080900A JP2012080900A (ja) | 2012-04-26 |
| JP2012080900A5 true JP2012080900A5 (https=) | 2012-11-08 |
Family
ID=36578383
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543226A Withdrawn JP2008520242A (ja) | 2004-11-18 | 2005-11-18 | 視覚障害を処置するための方法および組成物 |
| JP2012000185A Pending JP2012080900A (ja) | 2004-11-18 | 2012-01-04 | 視覚障害を処置するための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007543226A Withdrawn JP2008520242A (ja) | 2004-11-18 | 2005-11-18 | 視覚障害を処置するための方法および組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20090017029A1 (https=) |
| EP (1) | EP1836312B1 (https=) |
| JP (2) | JP2008520242A (https=) |
| KR (1) | KR101290621B1 (https=) |
| CN (2) | CN102618644A (https=) |
| AT (1) | ATE528410T1 (https=) |
| AU (1) | AU2005314461B2 (https=) |
| BR (1) | BRPI0518289A2 (https=) |
| CA (1) | CA2588270A1 (https=) |
| CY (1) | CY1112579T1 (https=) |
| DK (1) | DK1836312T3 (https=) |
| ES (1) | ES2375490T3 (https=) |
| IL (1) | IL183284A (https=) |
| WO (1) | WO2006062716A2 (https=) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004047514A2 (en) | 2002-11-25 | 2004-06-10 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
| WO2006128006A1 (en) | 2005-05-26 | 2006-11-30 | The Regents Of The University Of Colorado | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| SG10201804008UA (en) * | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| WO2007120975A2 (en) * | 2006-02-13 | 2007-10-25 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Variants in complement regulatory genes predict age-related macular degeneration |
| CA2638916A1 (en) * | 2006-02-13 | 2007-08-23 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| US8012683B2 (en) | 2006-02-13 | 2011-09-06 | University Of Iowa Research Foundation | Variants in complement regulatory genes predict age-related macular degeneration |
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| EP2479284B1 (en) * | 2006-07-13 | 2017-09-20 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
| AU2016204271B2 (en) * | 2006-07-13 | 2018-04-19 | University Of Iowa Research Foundation | Methods and reagents for the treatment and diagnosis of vascular disorders and age-related macular degeneration |
| ES2391788T3 (es) * | 2006-07-26 | 2012-11-29 | Yale University, Inc. | Diagnóstico y tratamiento de degeneración macular relacionada con la edad |
| CN101173314B (zh) * | 2006-10-18 | 2010-12-01 | 四川省医学科学院（四川省人民医院） | 检测老年黄斑变性疾病的试剂盒 |
| TW201716437A (zh) | 2006-11-02 | 2017-05-16 | 建南德克公司 | 人類化之抗-因子ｄ抗體及其用途 |
| GB0701213D0 (en) * | 2007-01-23 | 2007-02-28 | Univ Cardiff | Factor H polymorphisms in the diagnosis and therapy of inflammatory diseases such as age-related macular degeneration |
| WO2008103299A2 (en) | 2007-02-16 | 2008-08-28 | Massachusetts Eye & Ear Infirmary | Methods and compositions for prognosing, detecting, and treating age-related macular degeneration |
| CN101668773B (zh) | 2007-03-14 | 2016-08-31 | 亚力史制药公司 | 人工程化抗b因子抗体 |
| JP5226256B2 (ja) * | 2007-07-26 | 2013-07-03 | ニプロ株式会社 | 加齢黄斑変性症の発症リスクの予測方法 |
| WO2009059321A2 (en) * | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
| US8114592B2 (en) | 2008-03-18 | 2012-02-14 | Cambridge Enterprise Limited | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof |
| US20110190221A1 (en) * | 2008-03-28 | 2011-08-04 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
| DK2540843T3 (da) * | 2008-11-05 | 2014-09-01 | Genentech Inc | Genetiske polymorfismer ved aldersbetinget makulær degeneration |
| US20120115925A1 (en) * | 2008-12-23 | 2012-05-10 | Massachusetts Eye And Ear Infirmary | Allelic Variants Associated with Advanced Age-Related Macular Degeneration |
| KR100937720B1 (ko) * | 2009-04-20 | 2010-01-20 | 전남대학교산학협력단 | ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법 |
| WO2011003098A1 (en) | 2009-07-02 | 2011-01-06 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| CA2795311A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| US20130011857A1 (en) | 2010-02-12 | 2013-01-10 | Cemm Forschungszentrum Fur Molekulare Medizin Gmbh | Complement factor h for oxidative stress disease conditions |
| BR112012029067A2 (pt) | 2010-05-14 | 2019-09-24 | Univ Colorado Regents | grupos-alvo de receptor do complemento 2 (cr2) melhorados. |
| WO2011153234A2 (en) * | 2010-06-01 | 2011-12-08 | University Of Kentucky Research Foundation | Methods of inhibiting alu rna and therapeutic uses thereof |
| WO2011163394A2 (en) | 2010-06-22 | 2011-12-29 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| SG186397A1 (en) | 2010-06-22 | 2013-01-30 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3 |
| JP2014502953A (ja) | 2010-08-16 | 2014-02-06 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 細胞透過性治療薬の鼻腔内送達 |
| FR2983212A1 (fr) | 2011-11-28 | 2013-05-31 | Lfb Biotechnologies | Aptameres anti-fh, procede pour leur obtention et utilisations |
| FR2988298A1 (fr) * | 2012-03-23 | 2013-09-27 | Lfb Biotechnologies | Facteur h pour son utilisation comme molecule antioxydante |
| US9803005B2 (en) | 2012-05-24 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Humaneered anti-factor B antibody |
| CN102707068B (zh) * | 2012-05-31 | 2015-03-18 | 北京大学 | 补体h因子用作甲基苯丙胺成瘾患者的基因表达产物中的应用 |
| JP2015535212A (ja) | 2012-08-17 | 2015-12-10 | ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト | 補体活性化を検出するための組成物および方法 |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| MX366404B (es) | 2012-11-15 | 2019-07-08 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados. |
| AU2014236778B2 (en) | 2013-03-14 | 2019-01-03 | Baxalta GmbH | Factor H for transplantation |
| JP5721150B2 (ja) * | 2013-03-14 | 2015-05-20 | 学校法人 埼玉医科大学 | 加齢黄斑変性症の発症リスクの予測方法 |
| WO2014151923A1 (en) | 2013-03-14 | 2014-09-25 | Baxter International Inc. | Factor h for treatment of rheumatoid arthritis |
| AU2013202965B2 (en) | 2013-03-15 | 2016-07-21 | Takeda Pharmaceutical Company Limited | Improved method for producing factor h from a plasma precipitation fraction |
| WO2014152391A1 (en) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| SG11201601044XA (en) | 2013-08-12 | 2016-03-30 | Genentech Inc | Compositions and method for treating complement-associated conditions |
| US20150093331A1 (en) * | 2013-10-01 | 2015-04-02 | OncoLock Co., Ltd. | Biomarkers for breast cancer |
| KR102131973B1 (ko) * | 2013-12-30 | 2020-07-08 | 주식회사 케이티 | 개인 건강관리 방법 및 시스템 |
| ES2824262T3 (es) * | 2014-02-26 | 2021-05-11 | Allergan Inc | Anticuerpos contra componente C5 del complemento |
| US10155983B2 (en) | 2014-03-31 | 2018-12-18 | Machaon Diagnostics, Inc. | Method of diagnosis of complement-mediated thrombotic microangiopathies |
| AU2015253042A1 (en) | 2014-05-01 | 2016-10-20 | Genentech, Inc. | Anti-factor D antibody variants and uses thereof |
| KR102314785B1 (ko) * | 2015-04-21 | 2021-10-19 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 마커 및 황반변성 진단방법 |
| US11903994B2 (en) | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
| EP3368090A1 (en) | 2015-10-30 | 2018-09-05 | H. Hoffnabb-La Roche Ag | Anti-factor d antibody variant conjugates and uses thereof |
| CN106248968A (zh) * | 2015-11-01 | 2016-12-21 | 李倩 | 一种用于检测眼科疾病的试剂盒及其检测方法 |
| WO2017096031A1 (en) * | 2015-12-03 | 2017-06-08 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf |
| KR102011182B1 (ko) * | 2016-10-07 | 2019-08-16 | 단국대학교 천안캠퍼스 산학협력단 | 익상편 과발현 유전자 및 이의 용도 |
| IL269844B2 (en) | 2017-04-07 | 2025-01-01 | Apellis Pharmaceuticals Inc | Dosage regimens and related compositions and methods |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| US20210338838A1 (en) * | 2018-07-20 | 2021-11-04 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| KR102302571B1 (ko) * | 2019-03-07 | 2021-09-16 | (주)레티마크 | 나이관련 황반변성 진단용 복합 마커 및 이의 용도 |
| CA3167756A1 (en) * | 2020-02-04 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors |
| KR102333953B1 (ko) * | 2020-07-10 | 2021-12-02 | 인제대학교 산학협력단 | 신규한 황반변성 진단용 유전자 마커 |
| CN113293206A (zh) * | 2021-07-23 | 2021-08-24 | 西安医臻生物医药科技有限公司 | 一种快速鉴别老年黄斑病变风险的方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1284931C (en) * | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| CA2336703A1 (en) * | 1998-07-10 | 2000-01-20 | The University Of Sydney | Prophylactic treatments of neovascularisation in macular degeneration |
| AU2001245489A1 (en) * | 2000-03-07 | 2001-09-17 | Whitehead Institute For Biomedical Research | Human single nucleotide polymorphisms |
| JP4764590B2 (ja) * | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
| CN1466953A (zh) * | 2003-01-15 | 2004-01-14 | 哈佛东方生物医药（云南）有限公司 | 预防治疗老年黄斑变性的复合制剂 |
| US7745389B2 (en) * | 2005-02-14 | 2010-06-29 | University Of Iowa Research Foundation | Methods for treatment of age-related macular degeneration |
-
2005
- 2005-11-18 JP JP2007543226A patent/JP2008520242A/ja not_active Withdrawn
- 2005-11-18 WO PCT/US2005/041664 patent/WO2006062716A2/en not_active Ceased
- 2005-11-18 CN CN2012100868621A patent/CN102618644A/zh active Pending
- 2005-11-18 AU AU2005314461A patent/AU2005314461B2/en not_active Ceased
- 2005-11-18 AT AT05851755T patent/ATE528410T1/de active
- 2005-11-18 ES ES05851755T patent/ES2375490T3/es not_active Expired - Lifetime
- 2005-11-18 KR KR1020077013736A patent/KR101290621B1/ko not_active Expired - Fee Related
- 2005-11-18 CA CA002588270A patent/CA2588270A1/en not_active Abandoned
- 2005-11-18 US US11/791,025 patent/US20090017029A1/en not_active Abandoned
- 2005-11-18 CN CN2005800467319A patent/CN101142321B/zh not_active Expired - Fee Related
- 2005-11-18 DK DK05851755.8T patent/DK1836312T3/da active
- 2005-11-18 EP EP05851755A patent/EP1836312B1/en not_active Expired - Lifetime
- 2005-11-18 BR BRPI0518289-1A patent/BRPI0518289A2/pt not_active IP Right Cessation
-
2007
- 2007-05-17 IL IL183284A patent/IL183284A/en not_active IP Right Cessation
-
2011
- 2011-09-16 US US13/235,289 patent/US20120135000A1/en not_active Abandoned
-
2012
- 2012-01-04 JP JP2012000185A patent/JP2012080900A/ja active Pending
- 2012-01-11 CY CY20121100030T patent/CY1112579T1/el unknown
-
2013
- 2013-09-26 US US14/038,602 patent/US20140018306A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012080900A5 (https=) | ||
| Calero et al. | Apolipoprotein E genotyping method by Real Time PCR, a fast and cost-effective alternative to the TaqMan® and FRET assays | |
| Awe et al. | Evaluation of two MiniSTR loci mutation events in five Father-Mother-Child trios of Yoruba origin | |
| JP2012503985A5 (https=) | ||
| JP2017501685A5 (https=) | ||
| JP2014533949A5 (https=) | ||
| JP2019516375A5 (https=) | ||
| JP2017507130A5 (https=) | ||
| JP2010075182A5 (https=) | ||
| US10683548B2 (en) | Single nucleotide polymorphism in HLA-B*15:02 and use thereof | |
| RU2018122965A (ru) | Улучшенный способ и набор для определения тяжести и прогрессирования периодонтального заболевания | |
| JP2013544536A5 (https=) | ||
| RU2014126423A (ru) | Высокопроизводительный анализ однонуклеотидных полиморфизмов | |
| Schorderet et al. | IROme, a New High‐Throughput Molecular Tool for the Diagnosis of Inherited Retinal Dystrophies | |
| JP2010035532A (ja) | アレル特異的ｐｃｒ法 | |
| Ngoi et al. | High Resolution Melting Analysis for Rapid Mutation Screening in Gyrase and Topoisomerase IV Genes in Quinolone‐Resistant Salmonella enterica | |
| JP2013074888A (ja) | ＩＬ２８Ｂ（ｒｓ８０９９９１７）とＩＴＰＡ（ｒｓ１１２７３５４）の変異を検出する方法 | |
| Mitsunaga et al. | Improved loop-mediated isothermal amplification for HLA-DRB1 genotyping using RecA and a restriction enzyme for enhanced amplification specificity | |
| Chan et al. | Evaluation of nanofluidics technology for high-throughput SNP genotyping in a clinical setting | |
| CN104293968B (zh) | 一组用于检测非综合征性唇腭裂遗传易感性的多态性位点及检测试剂盒 | |
| Mehta et al. | High resolution melting (HRM) of forensically informative SNPs | |
| Zhang et al. | Analytical validation of a personalized medicine APOL1 genotyping assay for nondiabetic chronic kidney disease risk assessment | |
| Mahony et al. | Development of a novel bead-based multiplex PCR assay for combined subtyping and oseltamivir resistance genotyping (H275Y) of seasonal and pandemic H1N1 influenza A viruses | |
| Koehler et al. | High‐throughput genotyping of KIR2DL2/L3, KIR3DL1/S1, and their HLA class I ligands using real‐time PCR | |
| JP2018529377A5 (https=) |